Kirkland & Ellis LLP

06/12/2025 | Press release | Distributed by Public on 06/12/2025 11:22

Kirkland Assists Kelun-Biotech Biopharmaceutical on its H-Share Placing

Kirkland & Ellis represented the placing agents, including Goldman Sachs (Asia) L.L.C. and Citigroup Global Markets Limited, in connection with the H-share placing (the H-Share Placing) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (Kelun-Biotech). The H-Share Placing was announced on June 5, 2025 and completed on June 12, 2025.

The net proceeds from the H-Share Placing (after deducting all fees, costs and expenses incurred by Kelun-Biotech) amounted to approximately HKD 1.943 billion (USD 250 million). This represents the largest follow-on offering by a listed biotech company in Hong Kong over the past 12 months.

The Kirkland team included capital markets lawyers Mengyu Lu, George Zheng, Yuchen Han, Jing Du and Rock Liu.

Kirkland & Ellis LLP published this content on June 12, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 12, 2025 at 17:22 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io